A new Cleveland Clinic spinoff company has raised an initial $1 million to advance the development of a new therapeutic to take on Alzheimer’s and other neurological diseases. NeuroTherapia aims to commercialize NTRX-07, a drug that might be able to slow the symptoms of neurological diseases that are caused by inflammation. In animal trials, the compound has shown evidence of slowing the symptoms of neuro-inflammatory diseases.
Though Alzheimer’s is the first disease target, the company also aims to treat pain that occurs in people who have suffered nerve damage. Other neuro-inflammatory diseases include Parkinson’s and multiple sclerosis.
The compound, NTRX-07, is being developed by two Clinic doctors, Mohamed Naguib and Joseph Foss.